The US Food and Drug Administration has approved the second CAR T-cell therapy, indicated for certain types of non-Hodgkin lymphoma. READ MORE
A recent study showed improved long-term survival outcomes and QoL for patients with a B-cell malignancy receiving TKI therapy.
An analysis of over 39,000 patients with a certain B-cell malignancy showed improved survival outcomes after radiation therapy.
The high economic burden of B-cell malignancies on US commercial insurers may impact future reimbursement decisions.
Although some patients with DLBCL may be cured of their disease, risk of non-cancer causes of death is elevated in comparison with the general population.
The ICER has released a scoping document that will compare the clinical effectiveness and value of multiple CAR-T cell treatments under review by the FDA.
A recent study reported an ORR of 71% in patients with CLL treated with anti-CD19 CAR-T cell therapy after prior treatment failure.
The oncology nurses’ responsibility in monitoring and recognizing symptoms of CAR T-cell toxicities is especially important.
CD19-specific CAR T-cell therapy is more likely to be effective when given immediately after front-line therapy in patients with B-cell ALL.
The US Food and Drug Administration has approved the second CAR T-cell therapy, indicated for certain types of non-Hodgkin lymphoma.
Research in Review
The addition of a novel monoclonal antibody to ibrutinib significantly improves survival outcomes for patients with previously treated high-risk chronic lymphocytic leukemia.
An intravenous consolidation regimen developed for patients with chronic lymphocytic leukemia (CLL) was found to be safe and effective, according to a report in the European Journal of Hematology (2017;98:254-262).
Mutations in the BTK and PLCG2 genes have the potential to be used as a biomarker for relapse of chronic lymphocytic leukemia after treatment with ibrutinib.
Genomic profiling should be applied to patients with histiocytic disorders at diagnosis in order to guide targeted therapy.